Dublin, May 19, 2020 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

This report describes and evaluates the molecular diagnostics technologies that will play an important role in the practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.

The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals.

Molecular diagnostic markets are analyzed for 2019 according to technologies, applications and geographical regions. Forecasts are made up to 2029. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.

The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 268 of these are profiled in the report along with tabulation of 657 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.

Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions, is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare.

Molecular diagnostic technologies are also involved in the development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for point-of-care and biowarfare agents such as anthrax. Molecular diagnostic tests for COVID-19 are described

This was the first commercial report on this topic and published as "DNA Diagnostics" in 1995 by PJB Publications, UK. A new edition in 1997 "Molecular Diagnostics I" as well as the next edition, "Molecular Diagnostics II" in 1999, were published by Decision Resources Inc, USA. All the three versions of the reports were well received and sold widely. The report has been rewritten several times.

Key Topics Covered

Part I: Technologies & ApplicationsExecutive Summary1. Introduction2. Molecular Diagnostic Technologies3. Biochips, Biosensors and Nanobiotechnology4. Proteomic Technologies for Molecular Diagnostics5. Molecular Diagnosis of Genetic Disorders6. Molecular Diagnosis of Cardiovascular Disorders7. Molecular Diagnosis of Infections8. Molecular Diagnosis of Cancer9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare10. Molecular Diagnostics in Forensic Medicine and Biological Warfare11. References

Part II: Regulations, Markets and Companies12. Ethics, Patents and Regulatory Issues13. Markets for Molecular Diagnostics14. Companies Involved in Molecular Diagnostics

For more information about this report visit https://www.researchandmarkets.com/r/4envz6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:

Global Molecular Diagnostics Industry 2019-2029: Genetic Disorders, Cardiovascular Disorders, Infections and Cancer - Yahoo Finance UK